Marc Goodman

Pfizer-Bristol Drug Doesn’t Cut Leg Clots After Hospital Stay

Pfizer Inc. and Bristol-Myers Squibb Co.’s experimental drug apixaban wasn’t safer or more effective than a standard treatment in stopping blood clots in the legs and lungs of patients after hospitalization, a study found.

Lilly Says Alzheimer Patients Didn’t Improve

Eli Lilly & Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.

Pfizer Pill Leads Race to Dominate $12 Billion Arthritis Market

Pfizer Inc. , the world’s biggest drugmaker, leads a race against three rivals to sell the first new pill in a decade for rheumatoid arthritis, a joint disease treated by injected drugs with $12 billion in annual sales.

Breast Implant Link to Cancer Probed by U.S. FDA After 34 Cases Reported

Allergan Inc. and Johnson & Johnson breast implants were linked in a U.S. review to a rare type of cancer, challenging again the safety of the decades-old products.

Canadian Stocks Rise as Manufacturing Expands in U.S., China

Canadian stocks advanced for a third day, led by producers of base and precious metals and financial companies, after measures of manufacturing growth showed expansion in the U.S., China and Europe.

Bristol-Myers Profit Beats Analyst Estimates as Sales of Drugs Increase

Bristol-Myers Squibb Co ., whose top-selling blood thinner Plavix faces generic competition next year, reported first-quarter profit that was more than analysts’ estimates on higher drug sales.

Commodities Rally Is Drawing Investors Back to Funds, Kenmar's Shewer Says

Surging commodity prices are prompting investors to put more cash back into metals, grains and energy, according to Kenmar Group, which expects funds under management to grow by about a third to $2 billion by next March.

Merck, Pfizer Research Strategies Diverge on Spending

New chief executive officers at Merck & Co. and Pfizer Inc ., torn between profit demands of investors and the long-term funding needs of drug innovation, have chosen opposing strategies for future investment in research.

Teva Sees U.S. Health Law as `Opportunity;' Quarterly Profit Advances 31%

Teva Pharmaceutical Industries Ltd. , the world’s biggest maker of generic drugs, sees opportunity in the U.S. health-care overhaul as more people gain insurance coverage in the company’s biggest market.

Pfizer Profit Beats Analyst Estimates on Lower Costs

Pfizer Inc. , the world’s biggest drugmaker, reported third-quarter profit that topped analyst estimates after price increases and workforce reductions helped counter declining sales of the cholesterol pill Lipitor.

"It continues to be unclear to us if these events are harmful long-term or just short-term markers of drug efficacy."

- Marc Goodman on Jul 20, 2011

New York

New Brunswick

New Jersey

Shuanghui Agrees to Acquire Smithfield Foods for $4.72b

European Stocks Fall on Concern Fed Will Pare Stimulus

European Stocks Drop With Commodities as Yen Strengthens

U.S. Stocks Retreat Amid Concern Fed Will Taper Stimulus

SoftBank Gets National-Security Approval for Sprint Deal